睿知中国医院研究地图
候选清单

即将招募乳腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)

ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由烟台毓璜顶医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方烟台毓璜顶医院Yantai Yuhuangding Hospital烟台医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07054242,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed stage II-III (T1cN1-2 or T2-4N0-2) triple-negative breast cancer (TNBC), defined as:

    入选标准第 1 条

  3. Previous treatment with immune checkpoint inhibitors (anti-PD-1/L1, anti-CTLA-4) or T-cell targeting therapies.

    排除标准第 3 条

    Prior Trop-2 directed therapy or topoisomerase I inhibitor treatment.

    排除标准第 4 条

  4. ECOG performance status 0-1.

    入选标准第 6 条

  5. Absolute neutrophil count ≥1.5×10⁹/L (no G-CSF support within 14 days)

    入选标准第 8 条

    Platelets ≥100×10⁹/L (no transfusion within 14 days)

    入选标准第 9 条

    Hemoglobin >9 g/dL (no transfusion/ESA within 14 days)

    入选标准第 10 条

    Total bilirubin ≤1.5×ULN

    入选标准第 11 条

    AST/ALT ≤1.5×ULN

    入选标准第 12 条

    Alkaline phosphatase ≤2.5×ULN

    入选标准第 13 条

    Serum creatinine ≤1.5×ULN or CrCl ≥60 mL/min (Cockcroft-Gault)

    入选标准第 14 条

    INR/PT ≤1.5×ULN

    入选标准第 15 条

  6. At least one measurable lesion as per RECIST 1.1 criteria.

    入选标准第 5 条

  7. Other malignancies within 5 years (except adequately treated CIS of cervix, BCC, or cutaneous SCC).

    排除标准第 5 条

  8. For women of childbearing potential and men with WOCBP partners: agreement to use effective contraception from screening until 6 months post-treatment.

    入选标准第 19 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07054242,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Histologically or cytologically confirmed stage II-III (T1cN1-2 or T2-4N0-2) triple-negative breast cancer (TNBC), defined as:
  2. Immunohistochemistry (IHC) showing ER and PR <1%
  3. HER2-negative per 2028 ASCO-CAP guidelines (IHC 0/1+ or IHC 2+/ISH-)
  4. Available tumor tissue sample for biomarker analysis.
  5. At least one measurable lesion as per RECIST 1.1 criteria.
  6. ECOG performance status 0-1.
  7. Adequate organ function as evidenced by:
  8. Absolute neutrophil count ≥1.5×10⁹/L (no G-CSF support within 14 days)
  9. Platelets ≥100×10⁹/L (no transfusion within 14 days)
  10. Hemoglobin >9 g/dL (no transfusion/ESA within 14 days)
  11. Total bilirubin ≤1.5×ULN
  12. AST/ALT ≤1.5×ULN
  13. Alkaline phosphatase ≤2.5×ULN
  14. Serum creatinine ≤1.5×ULN or CrCl ≥60 mL/min (Cockcroft-Gault)
  15. INR/PT ≤1.5×ULN
  16. TSH within normal range (or normal FT3/FT4 if TSH abnormal)
  17. Normal cardiac enzymes (isolated abnormalities allowed if clinically insignificant)
  18. No prior anti-cancer therapy for current diagnosis.
  19. For women of childbearing potential and men with WOCBP partners: agreement to use effective contraception from screening until 6 months post-treatment.
  20. Willing and able to comply with study procedures and provide written informed consent.

排除标准:Exclusion Criteria:

  1. LVEF <50% by ECHO/MUGA or significant cardiac disease (NYHA Class III/IV).
  2. Prior chemotherapy, targeted therapy, or radiotherapy for current breast cancer.
  3. Previous treatment with immune checkpoint inhibitors (anti-PD-1/L1, anti-CTLA-4) or T-cell targeting therapies.
  4. Prior Trop-2 directed therapy or topoisomerase I inhibitor treatment.
  5. Other malignancies within 5 years (except adequately treated CIS of cervix, BCC, or cutaneous SCC).
  6. Severe ocular surface disease (dry eye syndrome, meibomian gland dysfunction, or corneal disorders impairing healing).
  7. Known hypersensitivity to study drug components.
  8. History of immunodeficiency disorders or organ transplantation.
  9. Current or history of:
  10. Steroid-requiring interstitial lung disease/pneumoniti Unresolved ILD/pneumonitis on screening imaging
  11. Recent pulmonary embolism (≤3 months)
  12. Severe asthma/COPD/restrictive lung disease
  13. Pleural effusion requiring intervention
  14. Connective tissue disease with pulmonary involvement
  15. Prior pneumonectomy
  16. Active autoimmune disease requiring systemic treatment (past 2 years), except:
  17. Hormone replacement therapy
  18. Physiologic corticosteroid replacement
  19. Active infection requiring systemic therapy within 14 days prior to initiation.
  20. Uncontrolled comorbidities that may:
  21. Compromise patient safety
  22. Interfere with study completion
  23. Any condition that in the investigator's judgment may:
  24. Affect study drug evaluation
  25. Compromise safety assessments
  26. Interfere with data interpretation
  27. Otherwise contraindicate participation

引自 ClinicalTrials.gov, NCT07054242, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07054242,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07054242